The estimated Net Worth of Ann L. Mac Dougall is at least $541 Thousand dollars as of 13 May 2022. Ms. Dougall owns over 3,000 units of Opiant Pharmaceuticals Inc stock worth over $540,596 and over the last 5 years she sold OPNT stock worth over $0. In addition, she makes $0 as Director at Opiant Pharmaceuticals Inc.
Ann has made over 5 trades of the Opiant Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 3,000 units of OPNT stock worth $32,790 on 13 May 2022.
The largest trade she's ever made was exercising 15,993 units of Opiant Pharmaceuticals Inc stock on 15 March 2021 worth over $159,930. On average, Ann trades about 2,410 units every 68 days since 2019. As of 13 May 2022 she still owns at least 26,179 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Ms. Dougall stock trades at the bottom of the page.
Ann L. MacDougall is Director of the Company. She has extensive global experience spanning both operating and legal roles for both private and non-profit organizations. Since January 2014, she has served as President of Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service. From 2007 to December 2013, Ms. MacDougall was Chief Operating Officer of Acumen, an investment fund focused on goods and services for low-income customers. Prior to Acumen, she had a long career managing legal matters at PriceWaterhouseCoopers, including as General Counsel in the U.S. and Deputy General Counsel based in Paris. Ms. MacDougall earned her B.A. at Tufts University and her J.D. at Brooklyn Law School.
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen, and Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include: